Effect Of Curcuma Xanthorrhiza and Vitamin D3 Supplementation in SLE Patients With Hypovitamin D
Launched by SAIFUL ANWAR HOSPITAL · May 13, 2017
Trial Information
Current as of June 03, 2025
Completed
Keywords
ClinConnect Summary
Cholecalciferol 1200 IU supplementation for 3 months in hypovitamin D SLE patients, decrease SLEDAI, however, it has not reached the mild activity and remission yet. Curcumin contained in Curcuma Xanthorrhiza; is an immunomodulator that has similar biological effect with vitamin D. Combination of curcumin and vitamin D are expected to work synergistically.
The subjects who fulfilled inclusion criteria, willing to participate in the research and signed the informed consent were 40 patients. Research subjects were randomized using simple randomization. The subjects were divided into 2 groups...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • SLE based on the criteria of American Collage of Rheumatology (ACR) 1997
- • Active SLE (SLEDAI\> 3)
- • 25(OH)D level \<30 ng/ml.
- Exclusion Criteria:
- • Pregnant
- • Taking supplements containing vitamin D and cur cumin
- • Had liver function disorders (SGOT/SGPT levels\> 2.5 times the upper normal limit)
- • Had impaired renal function (GFR \<25 ml/min)
- • Severe infections such as tuberculosis, pneumonia or HIV
About Saiful Anwar Hospital
Saiful Anwar Hospital is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. Renowned for its commitment to quality care and state-of-the-art facilities, the hospital actively engages in a variety of clinical studies aimed at evaluating new therapies, medical devices, and treatment protocols. With a multidisciplinary team of experienced healthcare professionals, Saiful Anwar Hospital prioritizes patient safety and ethical standards while contributing valuable insights to the medical community. The hospital's strategic focus on collaboration and excellence positions it as a pivotal player in the landscape of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Handono Kalim, Prof.
Principal Investigator
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials